S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Axonics Stock Forecast, Price & News

+1.94 (+3.43%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.04 million shs
Average Volume
448,443 shs
Market Capitalization
$2.76 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Stock Forecast (MarketRank)

Overall MarketRank

2.08 out of 5 stars

Medical Sector

505th out of 1,411 stocks

Surgical & Medical Instruments Industry

61st out of 137 stocks

Analyst Opinion: 2.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Axonics logo

About Axonics (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock News Headlines

Axonics (NASDAQ:AXNX) Stock Price Up 7%
Axonics: Q1 Earnings Snapshot
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$-80.07 million
Pretax Margin


Sales & Book Value

Annual Sales
$180.29 million
Book Value
$10.42 per share


Free Float
Market Cap
$2.76 billion
Not Optionable

Axonics Frequently Asked Questions

Should I buy or sell Axonics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axonics stock.
View analyst ratings for Axonics
or view top-rated stocks.

What is Axonics' stock price forecast for 2022?

7 analysts have issued twelve-month price targets for Axonics' shares. Their AXNX stock forecasts range from $62.00 to $79.00. On average, they expect Axonics' stock price to reach $70.17 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts' price targets for Axonics
or view top-rated stocks among Wall Street analysts.

How has Axonics' stock performed in 2022?

Axonics' stock was trading at $56.00 at the start of the year. Since then, AXNX stock has increased by 4.6% and is now trading at $58.57.
View the best growth stocks for 2022 here

When is Axonics' next earnings date?

Axonics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Axonics

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Thursday, May, 5th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.19. The firm earned $48.42 million during the quarter, compared to analysts' expectations of $45.37 million. Axonics had a negative trailing twelve-month return on equity of 16.54% and a negative net margin of 41.28%. The business's quarterly revenue was up 40.9% on a year-over-year basis. During the same period last year, the company posted ($0.46) EPS.
View Axonics' earnings history

What guidance has Axonics issued on next quarter's earnings?

Axonics updated its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $238.00 million-$238.00 million, compared to the consensus revenue estimate of $234.08 million.

Who are Axonics' key executives?

Axonics' management team includes the following people:

What is Raymond W. Cohen's approval rating as Axonics' CEO?

12 employees have rated Axonics CEO Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among Axonics' employees.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), (HON), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.37%), Vanguard Group Inc. (5.98%), Bellevue Group AG (4.35%), RTW Investments LP (3.70%), Loomis Sayles & Co. L P (3.27%) and Lord Abbett & CO. LLC (2.64%). Company insiders that own Axonics stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, Geoff Pardo, Jane E Kiernan, John Woock, Karen Noblett, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics

Which institutional investors are selling Axonics stock?

AXNX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, RTW Investments LP, Goldman Sachs Group Inc., Vanguard Group Inc., Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, and BlackRock Inc.. Company insiders that have sold Axonics company stock in the last two years include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics
or view top insider-selling stocks.

Which institutional investors are buying Axonics stock?

AXNX stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Next Century Growth Investors LLC, Champlain Investment Partners LLC, Bellevue Group AG, Loomis Sayles & Co. L P, Granite Investment Partners LLC, First Light Asset Management LLC, and Lisanti Capital Growth LLC.
View insider buying and selling activity for Axonics
or or view top insider-buying stocks.

How do I buy shares of Axonics?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $58.57.

How much money does Axonics make?

Axonics (NASDAQ:AXNX) has a market capitalization of $2.76 billion and generates $180.29 million in revenue each year. The company earns $-80.07 million in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Axonics have?

Axonics employs 517 workers across the globe.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for Axonics is www.axonics.com. The company can be reached via phone at (866) 722-5738, via email at [email protected], or via fax at 949-396-6321.

This page (NASDAQ:AXNX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.